Clinical Trial Update: An Extension of SKY-0515 in Participants With Huntington's Disease [Phase 2, Phase 3]

View source ↗

Summary

An extension study of SKY-0515 for Huntington's disease is enrolling by invitation in Phase 2/Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• SKY-0515

Snippet

Sponsor: Skyhawk Therapeutics, Inc. | Conditions: Huntington's Disease (HD) | Phase 2, Phase 3 | Status: ENROLLING_BY_INVITATION